• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

$2.8 million grant will fund preclinical study of new dementia treatment

Bioengineer by Bioengineer
October 7, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: UK Photo | Mark Cornelison

LEXINGTON, Ky. (Oct. 7, 2019) — The Sanders-Brown Center on Aging has received a five-year, $2.8 million grant to underwrite preclinical efficacy studies of a potential new treatment for dementia.

The drug candidate, called MW150, targets dysregulated brain inflammation driven by a stress-activated protein called p38?MAPK. The research is novel in that it is exploring efficacy in treating more than one form of dementia at the same time.

According to the Alzheimer’s Association, Alzheimer’s disease accounts for 60 to 80 percent of all dementia cases, but vascular cognitive impairment and dementia (VCID), caused by microscopic bleeding and blood vessel blockage in the brain, is the second most common cause.

“It’s extremely rare to see someone with only one type of dementia pathology in the brain,” said Linda Van Eldik, Director of the Sanders-Brown Center on Aging at the University of Kentucky and the grant’s principal investigator.

“Alzheimer’s disease and VCID pathology are frequently found together in the brains of older people, but little is known about how these two diseases interact and drive progression of dementia symptoms, though the evidence so far suggests it’s additive.”

As chronic neuroinflammation is a common feature seen early in both VCID and Alzheimer’s disease progression, Van Eldik’s work will test the idea that excessive inflammation in the brain driven by p38-MAPK worsens dementia symptoms and is therefore a good target for therapeutic intervention.

The study will use novel mouse models and Van Eldik’s recently developed drug candidate MW150, which (unlike most other dementia drug candidates) is able to cross the blood-brain barrier, increasing its potential therapeutic impact.

Van Eldik says this study is a key first step to understanding how to someday prevent or treat the growing number of elderly individuals afflicted by dementia with complex co-morbid pathologies.

“Given the urgency of the unmet medical need, particularly here in Kentucky where vascular disease is so prevalent, a new treatment either as a stand-alone therapy or as part of a multi-drug cocktail is a critical tool to fight an illness that threatens to overwhelm patients and their families physically, emotionally and financially,” Van Eldik said.

###

The National Institute on Aging, one of the U.S. National Institutes of Health, is the grantor.

Media Contact
Laura Wright
[email protected]
859-257-5307

Tags: AgingAlzheimerGerontologyMedicine/Healthneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

Japanese Catholic University Nursing Faculties Cultivate Distinct Values of Compassion, Dignity, and Service

October 23, 2025

Dual-Action Molecule Paves the Way for Advanced Kidney Disease Therapies

October 23, 2025

Retrons Unveiled: Advancing Precise Genome Editing

October 23, 2025

Glial Gene Rhythms Shift with Aging, Amyloid

October 23, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1276 shares
    Share 510 Tweet 319
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    307 shares
    Share 123 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    160 shares
    Share 64 Tweet 40
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    132 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Japanese Catholic University Nursing Faculties Cultivate Distinct Values of Compassion, Dignity, and Service

Dual-Action Molecule Paves the Way for Advanced Kidney Disease Therapies

Hypofractionated vs. Conventional Radiotherapy: Prostate Cancer Comparison

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.